Search results

tocilizumab (RoActerma)

Tocilizumab in combination with methotrexate is indicated for the treatment of juvenile idiopathic polyarthritis (rheumatoid factor positive or negative and extended oligoarthritis) in patients 2 years of age and older, who have responded inadequately to previous therapy with methotrexate. Tocilizumab can be given as monotherapy in case of intolerance to methotrexate or where continued treatment with methotrexate is inappropriate.

tocilizumab (RoActemra®)

In combination with methotrexate (MTX) for the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who have either responded inadequately to, or who were intolerant to previous therapy with one or more disease-modifying anti-rheumatic drugs (DMARDs) or tumour necrosis factor (TNF) antagonists. In these patients, tocilizumab can be given as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate. Tocilizumab has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function when given in combination with methotrexate.

tocilizumab (RoActemra)

Moderate to severe active rheumatoid arthritis

tocilizumab (RoActemra)

For the treatment of systemic Juvenile Idiopathic Arthritis

tocilizumab (RoActemra)

For the treatment of Giant Cell Arteritis (GCA) in adult patients.

tocilizumab (RoActemra)

Treatment of COVID-19 in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation.

tocilizumab (RoActemra)

for the treatment of monotherapy in rheumatoid arthritis (RA) when biologic combination with methotrexate (MTX) is inappropriate [e.g. due to intolerance to MTX].

tocilizumab (RoActemra®)

treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate.

tocilizumab (RoActemra®)

Treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate.

nirmatrelvir and ritonavir (Paxlovid®)

Treatment of COVID-19 in adults who do not require supplemental oxygen and who are at increased risk for progression to severe COVID-19.

remdesivir (Veklury)

Treatment of COVID-19 in: adults and paediatric patients (at least 4 weeks of age and weighing at least 3 kg) with pneumonia requiring supplemental oxygen (low- or high-flow oxygen or other non-invasive ventilation at start of treatment). adults and paediatric patients (weighing at least 40 kg) who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19.

SMC publishes a Collaborative Advice Document for treatments for COVID-19

SMC publishes a Collaborative Advice Document for treatments for COVID-19

molnupiravir (Lagevrio)

Treatment of mild to moderate coronavirus disease 2019 (COVID-19) in adults with a positive SARS-COV-2 diagnostic test and who have at least one risk factor for developing severe illness.

SMC publishes an updated Collaborative Advice Document for COVID-19 medicines; update for nirmatrelvir plus ritonavir (partial review of TA878)

SMC publishes an updated Collaborative Advice Document for COVID-19 medicines; update for nirmatrelvir plus ritonavir (Paxlovid) (partial review of TA878)

Two more COVID-19 treatments available through UK-wide initiative involving SMC

Two more medicines can now be used to treat COVID-19, thanks to a UK-wide multi-agency initiative involving the Scottish Medicines Consortium (SMC).